Fluoroetlnormemantine, a derivative of Memantine, is an antagonist of the N-metl-D-aspartate (NMDA) receptor. [18F]-Fluoroetlnormemantine can be used as a positron emission tomograp (PET) tracer. Fluoroetlnormemantine exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects[1][2][3].
Fluoroetlnormemantine (0.1-10 mg/kg; a single i.p.) shows anti-amnesic effects on Aβ 25-35-induced learning impairments in mice[1].
Fluoroetlnormemantine (0.1-10 mg/kg; i.p. once daily for 7 days) attenuates Aβ 25-35-induced behavioral deficits, neuroinflammation, oxidative stress, apoptosis, and cell loss in mice[1].
Fluoroetlnormemantine (1-20 mg/kg; a single injection) decreases behavioral despair in the forced swim test (FST) and reduces fear behavior in the cued fear conditioning (FC) and extinction training in rats[2].
| Animal Model: | Male Swiss CD-1 mice (7-9 weeks) were injected with Aβ25-35[1] |
| Dosage: | 0.1, 0.3, 1, 3, 10 mg/kg |
| Administration: | I.p. 30 minutes before the behavioral tests |
| Result: | Attenuated Aβ 25-35-induced spontaneous alternation deficit, passive avoidance deficit, and novel object exploration deficit. |
[1]. Couly S, et, al. Anti-Amnesic and Neuroprotective Effects of Fluoroetlnormemantine in a Pharmacological Mouse Model of Alzheimer's Disease. Int J Neuropsychopharmacol. 2021 Feb 15;24(2):142-157.
[2]. Chen BK, et, al. Fluoroetlnormemantine, a novel derivative of memantine, facilitates extinction learning without sensorimotor deficits. Int J Neuropsychopharmacol. 2021 Feb 25;pyab007.
[3]. Chen BK, et, al. Fluoroetlnormemantine, a novel NMDA receptor antagonist, for the prevention and treatment of stress-induced maladaptive behavior. Biological Psychiatry. 2021 May 9.